This inventor holds 3 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Astrazeneca Ab. Active years: 2008-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Mölndal, SE (2008)
- Göthenburg, SE (2024)
Company Filing History:
Years Active: 2008-2025
Title: Yafeng Xue: Innovator in Pharmaceutical Chemistry
Introduction
Yafeng Xue is a notable inventor based in Mölndal, Sweden. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target critical pathways in various diseases. With a total of 3 patents to his name, his work is paving the way for innovative treatments.
Latest Patents
Yafeng Xue's latest patents focus on substituted indazoles as IRAK4 inhibitors. The first patent describes chemical compounds of Formula (A) and their pharmaceutically acceptable salts, which inhibit IRAK4. These compounds have potential applications in treating respiratory diseases, cancer, inflammatory diseases, and autoimmune disorders. The second patent reiterates the significance of these compounds, emphasizing their utility in medicine.
Career Highlights
Yafeng Xue is currently associated with AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca involves research and development aimed at creating innovative therapies that address unmet medical needs. His expertise in chemical compounds has positioned him as a valuable asset in the pharmaceutical industry.
Collaborations
Yafeng collaborates with talented professionals in his field, including Ina Terstiege and Anna Ingrid Kristina Berggren. These collaborations enhance the research efforts and contribute to the advancement of innovative solutions in medicine.
Conclusion
Yafeng Xue's contributions to pharmaceutical chemistry through his patents and work at AstraZeneca AB highlight his role as an innovator in the field. His research on IRAK4 inhibitors is a testament to his commitment to developing effective treatments for various diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile